Infectious complications can result when early stone intervention prevents adequate antibiotic treatment or when surgical delay allows bacterial persistence. It’s important to optimize stone surgery ...

Trial results offer clinically important information on the efficacy and safety of the combination therapy in CKD with type 2 diabetes.

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

Adding an ICI to neoadjuvant chemotherapy can improve pCR rates and may improve OS in patients with MIBC, research suggests.

Higher all-cause and cardiovascular mortality predicted with concurrent hypertension and type 2 diabetes. (HealthDay News) — Adults with concurrent hypertension and type 2 diabetes (T2D) have high ...

(HealthDay News) — Compromised restoration of the skin barrier function of closed diabetic foot ulcers (DFUs), as measured by high transepidermal water loss (TEWL), is associated with increased odds ...

The researchers found that annual observed cardiac mortality exceeded expected from 2020 to 2023: 16 percent higher in 2020, 17 percent higher in 2021 and 2022, and 6 percent higher in 2023. Cardiac ...

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below.

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...